Expanding Horizons: Benda Pharmaceutical, Inc (BPMA.OB) Subsidiary Developing Potential AIDS Vaccine
Benda Pharmaceutical, Inc (BPMA.OB), a China-based pharmaceutical company that produces traditional Chinese medicines, conventional medicines, as well as Gendicine (the world's first commercialized gene therapy medicine for the treatment of cancer), announced today that its subsidiary "SiBiono" had made major strides in developing an anti-AIDS gene therapy. This breakthrough marks SiBiono's and Benda's anticipated intent to enter into the $14 billion Chinese anti-AIDS drug market. SiBiono is acknowledged as the leading biopharmaceutical pioneer commercializing the first publicly available gene therapy treatment. In May 2007, Japanese gene therapy research institute DNAVEC formed a joint venture with SiBiono to develop the SeV-Gag…